Page 11 - Summer 2019 Journal

(CAD). After 8 weeks of follow-up, the following indices were reduced in the coenzyme Q10 group: systolic and diastolic blood pressure, fasting and 2-h plasma insulin, glucose, triglycerides, lipid peroxides, malon-dialdehyde and diene conjugates. The following indi- ces were increased: HDL-cholesterol, vitamins A, C, E and beta-carotene (all changes P<0.05). The only changes in the group tak-
ing the B vita-
min complex
were increases
in vitamin C
and beta-caro-
tene (P<0.05).
These findings
indicate that
treatment with
coenzyme
Q10 decreases
blood pres-
sure possibly
by decreas-
ing oxidative
stress and in-
sulin response
in patients with known hypertension receiving conventional antihyperten- sive drugs.”
Just having a little bit of crazed, out-of-my-mind epiphany. I’ll keep you posted, and that’s a threat. I’m excited but also so very livid. Big Pharma is a criminal enterprise.
Laurie Lentz-Marino South Hadley, Massachusetts
VAERS AWARENESS PROJECT First I want to thank you for putting out such an excellent quarterly journal.
SUMMER2019
Letters
Every issue is well worth reading cover- to-cover. As the director of Vaccination Liberation for 20 years, I especially appreciate your excellent coverage of the vaccine issue.
With that said, I want to let other WAPF members know about the na- tional grassroots VAERS Awareness Project.
Even though it is a poor barometer of vaccine hazards, VAERS data are intimately involved in the licensing of vaccines. First, pre-licensure of a vac- cine is obtained by comparing a vaccine to another vaccine or to non-viral vac- cine contents; never to a placebo, which is the honored gold standard of scien- tific comparisons. After that limited formality is completed, post-licensure
is determined by compar- ing the num- ber of inju- ries reported to VAERS, as well as the cases adjudi- cated with the Vaccine Inju- ry Compen- sation Pro- gram, versus the number of vaccines distributed nationwide.
Obviously, distribution does not equal the number of vaccines actually used, and com- pensated injuries are admittedly a tiny fraction of the actual injuries known to
occur.
Vaccine package inserts admit that
product trials followed the subjects for only four to five days to monitor for adverse reactions. These trials are the only safety monitoring that occurs prior to FDA approval and licensing. This is why reporting vaccine adverse reac- tions to VAERS is essential to assess more accurately the injuries caused by
In 1986 the U.S. government barred parents from suing pharmaceu- tical companies for vaccine injuries and set up the Vaccine Adverse Event Reporting System (VAERS), a little- known mechanism whereby parents of vaccine-injured children can vol- untarily report such injuries and seek compensation from the government. Due to its obscurity, less than 1 percent of injuries are reported to VAERS, (https://healthit.ahrq.gov/sites/default/ files/docs/publication/r18hs017045- lazarus-final-report-2011.pdf).
Wise Traditions
9